Patient-Reported Outcomes Measurement Information System® Sleep Disturbance, Anxiety, Depression, Fatigue, and Pain Interference measures were administered.
Symptom frequency relationships, however, were moderated by the order in which the measures were administered.
These measures were administered approximately 15 weeks postdeployment and roughly a year and a half later.
The California Psychological Inventory, the Sixteen Personality Factor Questionnaire, and well-being measures were administered to 290 Romanian engineers.
The TABS and a variety of symptom, functional outcome, and cognitive measures were administered to 264 outpatients with schizophrenia/schizoaffective disorders at an initial assessment.
All measures were administered online via Qualtrics.
Measures were administered at baseline, postintervention, and 4-, 8-, and 12-month follow-ups.
These measures were administered to acutely ill schizophrenia patients enrolled in a 12-week study of antipsychotic medications (N596) and to their clinicians.
Along the same lines, no neuropsychological measures were administered to further understand the psychological functioning of the patient population at baseline or study completion.
All relevant measures were administered in each study, with the exception of loneliness, which was only administered in the ongoing study.
The therapy was conducted by JV; the observer-based measures were administered by a clinical psychologist, who was blinded to treatment allocation (JK).
